Back
ESC Premium Access

Timing of ejection fraction reassessment after sacubitril-valsartan initiation for indication to defibrillator implantation. A single center experience

Session: Device therapy e-posters
Topic: Implantable Cardioverter-Defibrillator (ICD)
Speaker: Doctor V. Carinci (Bologna, IT)
Event: ESC Congress 2021 - The Digital Experience

Congress Presentation

0

About the speaker

Doctor Valeria Carinci

Maggiore Hospital, Bologna (Italy)
0 follower

42 more presentations in this session

Intraoperative echocardiography for electrode implantation into the left bundle branch region in patients with indications for cardiac resynchronization therapy

Speaker: Doctor N. Pavlinova (Odessa, UA)

Access
Abstract
Slides
2
Thumbnail

Adherence to guidelines of diagnostic and therapeutic practices for suspected infections of cardiac implantable electronic devices

Speaker: Doctor G. De Ciancio (NANCY, FR)

Access
Abstract
Slides
0
Thumbnail

Prognostic effect of the electrocardiographic pattern following cardiac resincronization

Speaker: Mr J. Asensio Nogueira (Burgos, ES)

Access
Abstract
Slides
0
Thumbnail

Single- vs dual-chamber ICDs to prevent from inappropriate shocks: the debate is still alive

Speaker: Doctor S. Briongos Figuero (Madrid, ES)

Access
Abstract
Slides
0
Thumbnail

Validation of leadless atrioventricular synchronous pacing with Holter-ECG: a pilot study

Speaker: Doctor S. Briongos Figuero (Madrid, ES)

Access
Abstract
Slides
0
Thumbnail

Access the full session

Device therapy e-posters

Speakers: Doctor V. Carinci, Doctor N. Pavlinova, Doctor G. De Ciancio, Mr J. Asensio Nogueira, Doctor S. Briongos Figuero...
Access
0
Thumbnail

About the event

Image

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Congress
logo Image

Related content

ESC Premium Access

New foundational therapy in heart failure with reduced ejection fraction: should we keep following the 2016 European Society of Cardiology Heart Failure Guideline in 2021?

28 August 2021

Open Access

Evidence-based strategies to achieve low-risk status.

27 August 2021

Open Access

Long-term outcomes in PAH: Optimised approach to achieve the best outcomes.

27 August 2021

ESC 365 is supported by

logo Novo Nordisk